Clinical evidence based review and recommendations of aerosol generating medical procedures in otolaryngology – head and neck surgery during the COVID-19 pandemic
subject: review, aerosol, guideline, Aerosolization, COVID-19
description: Abstract Background Aerosol generating medical procedures (AGMPs) present risks to health care workers (HCW) due to airborne transmission of pathogens. During the COVID-19 pandemic, it is essential for HCWs to recognize which procedures are potentially aerosolizing so that appropriate infection prevention precautions can be taken. The aim of this literature review was to identify potential AGMPs in Otolaryngology - Head and Neck Surgery and provide evidence-based recommendations. Methods A literature search was performed on Medline, Embase and Cochrane Review databases up to April 3, 2020. All titles and abstracts of retrieved studies were evaluated and all studies mentioning potential AGMPs were included for formal review. Full text of included studies were assessed by two reviewers and the quality of the studies was evaluated. Ten categories of potential AGMPs were developed and recommendations were provided for each category. Results Direct evidence indicates that CO2 laser ablation, the use of high-speed rotating devices, electrocautery and endotracheal suctioning are AGMPs. Indirect evidence indicates that tracheostomy should be considered as potential AGMPs. Nasal endoscopy and nasal packing/epistaxis management can result in droplet transmission, but it is unknown if these procedures also carry the risk of airborne transmission. Conclusions During the COVID-19 pandemic, special care should be taken when CO2 lasers, electrocautery and high-speed rotating devices are used in potentially infected tissue. Tracheal procedures like tracheostomy and endotracheal suctioning can also result in airborne transmission via small virus containing aerosols.
creator: Andrew Thamboo, Yuqi Wu, Jane Lea, Doron D. Sommer, Jennifer Ham, Leigh Sowerby, Arman Abdalkhani, Christopher Diamond, Austin Heffernan, M. Cai Long, Jobanjit Phulka, Phillip Yeung, Marc Lammers
source: Journal of Otolaryngology - Head and Neck Surgery
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s40463-020-00425-6
coverage: Surgery

Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?
subject: infection, hypertension, SARS, SARS-CoV-2, COVID-19, 2019 novel coronavirus
description: Abstract Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic.
creator: Jin Ho Shin, Dae-Hee Kim, Hyeon Chang Kim, Ju Han Kim, Sungha Park, Eun Joo Cho, Hae-Young Lee, Kwang-Il Kim, Wook-Jin Chung, Sang Hyun Ihm, Il Suk Sohn, Wook Bum Pyun, Ki-Chul Sung, Sung Kee Ryu, on behalf of the Korean Society of Hypertension
source: Clinical Hypertension
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s40885-020-00144-0
coverage: Internal medicine, Medicine

Ideas for how informaticians can get involved with COVID-19 research
description: Abstract The coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on population health and wellbeing. Biomedical informatics is central to COVID-19 research efforts and for the delivery of healthcare for COVID-19 patients. Critical to this effort is the participation of informaticians who typically work on other basic science or clinical problems. The goal of this editorial is to highlight some examples of COVID-19 research areas that could benefit from informatics expertise. Each research idea summarizes the COVID-19 application area, followed by an informatics methodology, approach, or technology that could make a contribution. It is our hope that this piece will motivate and make it easy for some informaticians to adopt COVID-19 research projects.
creator: Li Shen, Yong Chen, George Demiris, Marylyn D. Ritchie, Jason H. Moore, Jeffrey S. Morris, John H. Holmes, Ryan Urbanowicz, Dokyoon Kim, Rebecca A. Hubbard, Ian Barnett, Blanca E Himes, Graciela Gonzalez-Hernandez, Daniel S Herman, Danielle L. Mowery, Mary Regina Boland
source: BioData Mining
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s13040-020-00213-y
coverage: Computer applications to medicine. Medical informatics, Analysis

Together we unite: the role of the Commonwealth in achieving universal health coverage through pharmaceutical care amidst the COVID-19 pandemic
subject: Health, commonwealth, Pharmacy, Pharmacists, Pandemic, Heads of government
description: Abstract The world currently faces unprecedented health challenges as COVID-19 poses a huge threat to health systems, economies and societies as we know it. The events of the current COVID-19 pandemic have further emphasised existing issues within our health systems. There is no better time than now to come together in global solidarity to tackle these evolving threats of COVID-19 pandemic. The Commonwealth is an ideally placed network to tackle these global health challenges, with its wide-reaching networks of governmental, non-governmental and civil society organisations across all continents. Although the biennial Commonwealth Heads of Government Meeting (CHOGM) originally scheduled to take place in Kigali in Rwanda 22–27 June 2020 has been postponed in view of COVID-19, Commonwealth country discussions are continuing, centred on the CHOGM key theme of ‘Delivering a Common Future: Connecting, Innovating, Transforming’, and five subthemes of Information and Communications Technology (ICT) and Innovation; Trade; Environment; Governance and the Rule of Law; and Youth. The planned CHOGM and Commonwealth itself provides all members a timely platform to consider innovative ways to connect, innovate and transform healthcare to meet the needs of their populations. This commentary considers these five CHOGM subthemes and how member nations can be supported to achieve universal health coverage through optimising medicines use and outcomes, in the midst of a global pandemic in line with the global health agenda.
creator: Zaheer-ud-din Babar, Diane Ashiru-Oredope, Chloe Tuck, Amy Hai Yan Chan, Victoria Rutter
source: Journal of Pharmaceutical Policy and Practice
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s40545-020-00214-6
coverage: Therapeutics. Pharmacology, Pharmacy and materia medica

Current regulatory approaches for accessing potential COVID-19 therapies
subject: FDA, clinical studies, regulatory, EMA, Compassionate use, COVID-19
description: Abstract This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials. Since no therapies have been formally approved and completely effective and safe to date, the best clinical choice is acquired only after consistent and fair communication and collaboration between licensed clinicians, researchers, regulatory authorities, manufacturers and patients.
creator: Armond Daci, Aleksandra Grozdanova, Milena Stevanovic, Irina Panovska-Stavridis, Vesa Halimi, Simona Stojanovska, Venko Filipce
source: Journal of Pharmaceutical Policy and Practice
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s40545-020-00222-6
coverage: Therapeutics. Pharmacology, Pharmacy and materia medica

The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the “cytokine storm” in COVID-19 patients: a hypothesis
subject: Acute lung injury, acute respiratory distress syndrome, Cytokine storm, SARS-CoV-2, COVID-19, LMWF5A
description: Abstract Background A common complication of viral pulmonary infections, such as in the ongoing COVID-19 pandemic, is a phenomenon described as a “cytokine storm”. While poorly defined, this hyperinflammatory response results in diffuse alveolar damage. The low molecular weight fraction of commercial human serum albumin (LMWF5A), a novel biologic in development for osteoarthritis, demonstrates beneficial in vitro immunomodulatory effects complimentary to addressing inflammation, thus, we hypothesize that LMWF5A could improve the clinical outcomes of COVID-19 by attenuating hyperinflammation and the potential development of a cytokine storm. Presentation of the hypothesis A variety of human in vitro immune models indicate that LMWF5A reduces the production of pro-inflammatory cytokines implicated in cytokine storm associated with COVID-19. Furthermore, evidence suggests LMWF5A also promotes the production of mediators required for resolving inflammation and enhances the barrier function of endothelial cultures. Testing the hypothesis A randomized controlled trial, to evaluate the safety and efficacy of nebulized LMWF5A in adults with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection, was developed and is currently under review by the Food and Drug Administration. Implications of hypothesis If successful, this therapy may attenuate the cytokine storm observed in these patients and potentially reduce mortality, increase ventilation free days, improve oxygenation parameters and consequently lessen the burden on patients and the intensive care unit. Conclusions In conclusion, in vitro findings suggest that the immunomodulatory effects of LMWF5A make it a viable candidate for treating cytokine storm and restoring homeostasis to the immune response in COVID-19.
creator: David Bar-Or, Laura Goldberg, Michael Roshon, Charles Mains, Gregory Thomas, Elizabeth Frederick, Melissa Hausburg, Marshall Hoke
source: Patient Safety in Surgery
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s13037-020-00248-4
coverage: Surgery

Introducing the “Corona Curtain”: an innovative technique to prevent airborne COVID-19 exposure during emergent intubations
subject: Intubation, coronavirus, SARS-CoV-2, COVID-19, Viral exposure
description: Abstract Background The coronavirus disease 2019 (COVID-19) pandemic places healthcare workers at risk of exposure to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Emergency department (ED) staff are particularly vulnerable when managing patients with acute respiratory distress due to the aerosolization of the virus during endotracheal intubation. A simple and innovative intubation tent was designed with the intent of decreasing the risk of accidental viral transmission from emergent intubations during the COVID-19 pandemic. Presentation of technique The materials and assembly process of the novel “Corona Curtain” are described in technical detail, with the intent of allowing other providers to template the concept at their respective facilities. Results A total of 36 intubation tents were mounted in the ED at the Medical Center of Aurora, Colorado, on April 7, 2020, and thereafter consistently used for all intubations during the ongoing COVID-19 outbreak. The cost of raw materials and labor for the initial assembly averaged US $ 8.00 per construct. The price of the single-use plastic cover is variable depending on the vendor source. Conclusion The new “Corona Curtain” was designed to improve the safety of ED staff when performing urgent/emergent intubations during the current COVID-19 pandemic. The concept can easily be adopted to other patient care areas, including perioperative and intensive care units. Future validation studies are needed to determine the safety and efficacy of the intubation tents by quantifying the pre−/post-intubation exposure through “point-of-care” SARS-CoV-2 testing once these resources are more widely available.
creator: Philip F. Stahel, Eric Hill, Christopher Crockett, Ryan W. Circh, Frank Lansville
source: Patient Safety in Surgery
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s13037-020-00247-5
coverage: Surgery

Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
subject: cancer, Outcomes, clinical characteristics, SARS-CoV-2
description: Abstract In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be greatly increased, so we will report clinical features of 9 cancer patients with SARS-CoV-2 infection. 5 (56%) patients were ordinary type, 3 (33%) were severe type, and 1 (11%) was critical type. A total of 8 patients received combined therapy of traditional Chinese medicines and western medicines. From the clinical outcomes of these 8 patients, western combined therapy of traditional Chinese medicine was indeed an effective treatment method. D-dimmer rise, infection index rise, and chest CT(computed tomography) progression may be clinical warning indicators for severe patients, in our study, more 50% of patients had elevated levels of these indicators, but only 44% (including the dead) of patients had received treatment in the intensive care unit. 5 (56%) ordinary type patients had been discharged, while the 1 (11%) critical type patient died 3 days after admission. Cancer comorbidity seems to have no direct relationship with severe events, and the combination of traditional Chinese medicine and western medicine may be effective in the prevention and treatment of novel coronavirus-infected pneumonia (NICP).
creator: Bo Zhang, Yong Zeng, Xufeng Zhang, Cun-Jian Yi
source: Chinese Medicine
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s13020-020-00328-8
coverage: Other systems of medicine

Aerosol-generating otolaryngology procedures and the need for enhanced PPE during the COVID-19 pandemic: a literature review
subject: PPE, personal protective equipment, COVID-19, Otolaryngology - head and neck surgery, AGMP, Aerosol generating medical procedure
description: Abstract Background Adequate personal protective equipment is needed to reduce the rate of transmission of COVID-19 to health care workers. Otolaryngology groups are recommending a higher level of personal protective equipment for aerosol-generating procedures than public health agencies. The objective of the review was to provide evidence that a.) demonstrates which otolaryngology procedures are aerosol-generating, and that b.) clarifies whether the higher level of PPE advocated by otolaryngology groups is justified. Main body Health care workers in China who performed tracheotomy during the SARS-CoV-1 epidemic had 4.15 times greater odds of contracting the virus than controls who did not perform tracheotomy (95% CI 2.75–7.54). No other studies provide direct epidemiological evidence of increased aerosolized transmission of viruses during otolaryngology procedures. Experimental evidence has shown that electrocautery, advanced energy devices, open suctioning, and drilling can create aerosolized biological particles. The viral load of COVID-19 is highest in the upper aerodigestive tract, increasing the likelihood that aerosols generated during procedures of the upper aerodigestive tract of infected patients would carry viral material. Cough and normal breathing create aerosols which may increase the risk of transmission during outpatient procedures. A significant proportion of individuals infected with COVID-19 may not have symptoms, raising the likelihood of transmission of the disease to inadequately protected health care workers from patients who do not have probable or confirmed infection. Powered air purifying respirators, if used properly, provide a greater level of filtration than N95 masks and thus may reduce the risk of transmission. Conclusion Direct and indirect evidence suggests that a large number of otolaryngology-head and neck surgery procedures are aerosol generating. Otolaryngologists are likely at high risk of contracting COVID-19 during aerosol gen…
creator: Paul Mick, Russell Murphy
source: Journal of Otolaryngology - Head and Neck Surgery
publisher: BMC
date: 2020
identifier: DOI: 10.1186/s40463-020-00424-7
coverage: Surgery

COVID-19 - ESSKA guidelines and recommendations for resuming elective surgery
description: Abstract The roadmap to elective surgery resumption after this COVID-19 pandemic should be progressive and cautious. The aim of this paper was to give recommendations and guidelines for resuming elective orthopedic surgery in the safest environment possible. Elective surgery should be performed in COVID-free facilities and hospital stay should be as short as possible. For matters of safety, patients considered first for surgery should be carefully selected according to COVID infection status/exposure, age, ASA physical status classification system / risk factors, socio-professional situation and surgical indication. A strategy for resuming elective surgery in four phases is proposed. Preoperative testing for COVID-19 infection is highly recommended. In any cases, COVID symptoms including fever and increased temperature should be constantly monitored until the day of surgery. Elective surgery should be postponed at the slightest suspicion of a COVID-19 infection. In case of surgery, adapted personal protective equipment in terms of gowns, gloves, masks and eye protection is highly recommended and described.
creator: Michael T Hirschmann, Matthieu Ollivier, Romain Seil, Jacques Menetrey, Caroline Mouton
source: Journal of Experimental Orthopaedics
publisher: SpringerOpen
date: 2020
identifier: DOI: 10.1186/s40634-020-00248-4
coverage: Orthopedic surgery